Clinical Trial

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

Study acronym: CAMIL
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.
Trial Details
NCT Number NCT04824950
Lead Sponsor Centre Henri Becquerel
Conditions Primary Mediastinal Large B-cell Lymphoma
Enrollment 87 participants
Start Date 2021-03-22
Primary Completion 2028-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2021-04-01